Drugs and Medicine

Insulin Glargine

Question: what is the consequences of mixing insulin aspart and insulin glargine?

Answer: mixing different insulins can affect the peak performance time of both and could result in a severe hypo episode.

 


Insulin Glargine Related Products and News

Insulin Degludec Matches Insulin Glargine Efficacy

Family Practice News Digital Network
Insulin degludec, an ultralong-acting insulin now in clinical development, proved noninferior to insulin glargine in two parallel, phase III randomized trials sponsored by the manufacturer and reported in the April 21 issue of Lancet.
 

Two phase 3 studies on ultra-long-acting insulin degludec published today in ...

PharmaLive.com (press release)
The two phase 3 studies included in total 1635 participants and investigated insulin degludec compared to insulin glargine in a basal-bolus regimen in people with type 1 and type 2 diabetes.1,2 Both studies were 'treat-to-target' studies, ...
 

Insulin degludec

Diabetes Health (press release)
The phase 3 studies looked at 1635 people and compared the new insulin with a standard insulin glargine. It appeared effective for both type 1 and type 2 diabetes. For type 2s, it reduced the number of low blood sugar episodes to 11.1 per year, ...
 

Extension Study of Bydureon Shows Positive Results

Family Practice News Digital Network
Following 84 weeks of treatment, patients with type 2 diabetes who received exenatide once weekly experienced better glycemic control with sustained overall weight loss and a lower risk of hypoglycemia, compared with those who received insulin glargine ...
 

Wider Loss at Amylin

Zacks.com
Byetta should also benefit from the recent approval under which it can be used in combination with insulin glargine, with or without metformin and/or a TZD, for the treatment of type II diabetes in patients who are not achieving adequate glycemic ...
 

Abbott Announces Collaboration with Syngene to Open First Nutrition R&D Center ...

MarketWatch (press release)
Biocon's key innovations include the world's first Pichia-based recombinant human Insulin, INSUGEN®, insulin analog Glargine, BASALOG® and India's first indigenously produced monoclonal antibody, BioMAb-EGFR®, for head & neck cancer.
 

New York Times

Amylin Pharmaceuticals Reports First Quarter 2012 Financial Results
MarketWatch (press release)
 

NICE threshold 'could be reduced to £13000 per QALY'

Pulse
They have calculated that it could be lowered by at least £10000 per QALY, and potentially reduced to as little as £13000, in a move would have meant that drugs such as dabigatran and insulin glargine would never have been approved for use on the NHS.
 

On The Pulse - 27th April 2012

OnMedica
Two trials in the Lancet ? one in type 1 diabetes , one in type 2 ? investigate insulin degludec, which after injection forms multihexamer chains in subcutaneously, yielding a slower, steadier release. Both studies compared it with insulin glargine, ...
 

The Star-Ledger - NJ.com

Sanofi's strong 1st-qtr driven by Genzyme
The Pharma Letter